

# Sven Mahner

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3460568/sven-mahner-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

222  
papers

3,638  
citations

23  
h-index

55  
g-index

248  
ext. papers

4,862  
ext. citations

4.5  
avg, IF

4.93  
L-index

#	Paper	IF	Citations
222	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2154-2164	59.2	1259
221	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 87-97	21.7	405
220	Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	117
219	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1358-66	8.7	91
218	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 15-21	4.9	86
217	Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 242-8	2.2	79
216	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 699-709	21.7	62
215	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 1327-1331	3.5	49
214	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1247-1258	21.7	49
213	Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynkologische Onkologie CaRE-1 multicenter study. <i>European Journal of Cancer</i> , <b>2016</b> , 69, 180-188	7.5	47
212	Vitamin D and VDR in Gynecological Cancers-A Systematic Review. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	37
211	Patterns of distant metastases in vulvar cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 427-34	4.9	36
210	TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. <i>BMC Cancer</i> , <b>2010</b> , 10, 139	4.8	32
209	Role of Placental VDR Expression and Function in Common Late Pregnancy Disorders. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	31
208	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 587-590	2.2	30
207	Clinical management of epithelial ovarian cancer during pregnancy. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 963-71	7.5	28
206	Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF-7 and MDA-MB-231 breast carcinoma cells. <i>Oncology Reports</i> , <b>2019</b> , 41, 387-396	3.5	28

205	Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results. <i>Brachytherapy</i> , <b>2018</b> , 17, 775-781	2.4	26
204	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , <b>2017</b> , 8, 106415-106428	3.3	25
203	Systemic treatment of vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 629-37	3.5	25
202	Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review). <i>Oncology Reports</i> , <b>2016</b> , 35, 1905-15	3.5	24
201	Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 1314-1321	3.1	23
200	Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , <b>2014</b> , 25, 221-8	4	23
199	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 61-68	4.9	22
198	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5411-5423	12.9	21
197	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. <i>Tumor Biology</i> , <b>2016</b> , 37, 3009-16	2.9	21
196	Placental Expression Patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in Cases of Intrauterine Growth Restriction (IUGR). <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 523	6.3	20
195	Efficacy and safety of niraparib as maintenance treatment in older patients (≥70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 560-567	4.9	19
194	HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 1563-9	4.4	17
193	Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 20,	6.3	17
192	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. <i>Epigenetics</i> , <b>2013</b> , 8, 1226-35	5.7	16
191	PPARγ Expression Is Diminished in Macrophages of Recurrent Miscarriage Placentas. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	15
190	Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients. <i>BMC Cancer</i> , <b>2018</b> , 18, 141	4.8	15
189	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 211	5.3	15
188	Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 286-291	4.9	15

187	Sexual activity and quality of life in patients after treatment for breast and ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , <b>2019</b> , 299, 191-201	2.5	15
186	Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	15
185	LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1508-1526	7.9	14
184	The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	14
183	Loss of promotor hypermethylation in recurrent high-grade ovarian cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 83063-83074	9.9	14
182	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 431	4.8	13
181	The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	12
180	Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 419-428	3.9	12
179	A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2012</b> , 138, 1413-9	4.9	12
178	Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165705	3.7	12
177	Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. <i>Oncotarget</i> , <b>2018</b> , 9, 982-994	3.3	12
176	Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	12
175	Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 249-256	4.9	12
174	Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations. <i>Oncology Letters</i> , <b>2017</b> , 13, 2495-2501	2.6	11
173	Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
172	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , <b>2019</b> , 17, 537-560	6.8	11
171	Fetal gender specific expression of tandem-repeat galectins in placental tissue from normally progressed human pregnancies and intrauterine growth restriction (IUGR). <i>Placenta</i> , <b>2015</b> , 36, 1352-61	3.4	11
170	Prostaglandin E receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses. <i>Endocrine Connections</i> , <b>2018</b> , 7, 749-761	3.5	11

169	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, 175-183	3	11
168	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , <b>2016</b> , 17, 643	4.5	11
167	The Formation and Therapeutic Update of Tumor-Associated Macrophages in Cervical Cancer. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	11
166	A systematic model specification procedure for an illness-death model without recovery. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123489	3.7	11
165	EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 6053-6068	4.4	10
164	Anti $\alpha$ -enolase antibody is a novel autoimmune biomarker for unexplained recurrent miscarriages. <i>EBioMedicine</i> , <b>2019</b> , 41, 610-622	8.8	10
163	M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis. <i>Cells</i> , <b>2020</b> , 9,	7.9	10
162	Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 565-570	4.9	9
161	Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. <i>Breast Cancer: Targets and Therapy</i> , <b>2019</b> , 11, 87-97	3.9	9
160	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , <b>2018</b> , 149, 371-380	4.9	9
159	Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 571-576	4.9	9
158	Errestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 554733	5.7	9
157	Well-being during COVID-19 pandemic: A comparison of individuals with minoritized sexual and gender identities and cis-heterosexual individuals. <i>PLoS ONE</i> , <b>2021</b> , 16, e0252356	3.7	9
156	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2017</b> , 17, 279-285	3	8
155	MR pelvimetry: prognosis for successful vaginal delivery in patients with suspected fetopelvic disproportion or breech presentation at term. <i>Archives of Gynecology and Obstetrics</i> , <b>2017</b> , 295, 351-359	2.5	8
154	Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	8
153	High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
152	Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases. <i>Radiation Oncology</i> , <b>2018</b> , 13, 25	4.2	8

151	Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 7673-7684	3.6	8
150	Induction of DNA damage and apoptosis in human leukemia cells by efavirenz. <i>Oncology Reports</i> , <b>2017</b> , 37, 617-621	3.5	8
149	TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO-OVAR OP7).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5602-TPS5602	2.2	8
148	Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients. <i>Cancers</i> , <b>2019</b> , 11,	6.6	8
147	Involvement of ILR4 and TLR4 in miscarriages. <i>Journal of Reproductive Immunology</i> , <b>2019</b> , 131, 36-43	4.2	8
146	Placental Galectin-2 Expression in Gestational Diabetes: A Systematic, Histological Analysis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
145	Histone H3 lysine 9 acetylation is downregulated in GDM Placentas and Calcitriol supplementation enhanced this effect. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	8
144	Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. <i>Oncology Letters</i> , <b>2017</b> , 14, 3302-3308	2.6	7
143	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 832	5.3	7
142	Prognostic relevance of RIP140 and ER expression in unifocal versus multifocal breast cancers: a preliminary report. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	7
141	Glucocorticoid receptors and are modulated sex specifically in human placentas of intrauterine growth restriction (IUGR). <i>Archives of Gynecology and Obstetrics</i> , <b>2019</b> , 300, 323-335	2.5	7
140	Cytoplasmic PPAR is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 94	8.5	7
139	Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3501-3501	2.2	7
138	p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 224, 595.e1-595.e11	6.4	7
137	Hormone Receptor Expression in Multicentric/Multifocal versus Unifocal Breast Cancer: Especially the VDR Determines the Outcome Related to Focality. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	7
136	Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium. <i>Histochemistry and Cell Biology</i> , <b>2018</b> , 149, 153-160	2.4	7
135	A randomized trial comparing limited-excision conisation to Large Loop Excision of the Transformation Zone (LLETZ) in cervical dysplasia patients. <i>Journal of Gynecologic Oncology</i> , <b>2019</b> , 30, e42	4	6
134	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 111	8.3	6

133	PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 569-577	4.9	6
132	In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines. <i>International Journal of Molecular Medicine</i> , <b>2016</b> , 38, 1296-302	4.4	6
131	Expression of Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16 in cervical dysplasia. <i>Future Oncology</i> , <b>2017</b> , 13, 145-157	3.6	6
130	Early Life Oxidative Stress and Long-Lasting Cardiovascular Effects on Offspring Conceived by Assisted Reproductive Technologies: A Review. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
129	Interleukin-1 beta is significantly upregulated in the decidua of spontaneous and recurrent miscarriage placentas. <i>Journal of Reproductive Immunology</i> , <b>2021</b> , 144, 103283	4.2	6
128	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
127	Glucocorticoid receptor in cervical cancer: an immunohistochemical analysis. <i>Archives of Gynecology and Obstetrics</i> , <b>2019</b> , 299, 203-209	2.5	6
126	Prognostic impact of residual disease in simultaneous additional excision specimens after one-step breast conserving therapy with negative final margin status in primary breast cancer. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1318-1323	3.6	6
125	EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 2519-2527	4.9	5
124	Cell Type- and Sex-Specific Dysregulation of Thyroid Hormone Receptors in Placentas in Gestational Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
123	Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor $\beta$ Are Inversely Associated with Survival in Primary Breast Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
122	Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening. <i>Archives of Gynecology and Obstetrics</i> , <b>2018</b> , 297, 1533-1538	2.5	5
121	Adjuvant therapy in node-positive vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 839-44	3.5	5
120	Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5007-5007	2.2	5
119	LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1548-1553	3.5	5
118	The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro. <i>Cells</i> , <b>2021</b> , 10,	7.9	5
117	Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2189-2203	4.9	4
116	H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1 $\alpha$ ,25(OH)2D3) in Ovarian Cancer Biology. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4

115	MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
114	miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3560-3573	7.5	4
113	The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases. <i>Scientific Reports</i> , <b>2020</b> , 10, 1154	4.9	4
112	Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study. <i>Strahlentherapie Und Onkologie</i> , <b>2019</b> , 195, 289-296	4.3	4
111	A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5625-TPS5625	2.2	4
110	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube	2.2	4
109	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6068-6068	2.2	4
108	The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7). <i>Anticancer Research</i> , <b>2017</b> , 37, 95-102	2.3	4
107	Sex Specific Expression of Interleukin 7, 8 and 15 in Placentas of Women with Gestational Diabetes. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
106	Epigenetic modification via H3K4me3 and H3K9ac in human placenta is reduced in preeclampsia. <i>Journal of Reproductive Immunology</i> , <b>2021</b> , 145, 103287	4.2	4
105	Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	4
104	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , <b>2020</b> , 41, 442-451	4.6	4
103	G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 564002	5.7	4
102	Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
101	Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. <i>Anticancer Research</i> , <b>2009</b> , 29, 2817-21	2.3	4
100	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , <b>2016</b> , 36, 1015-22	2.3	4
99	Short interval between two Pap smears: effect on the result of the second smear? A prospective randomized trial. <i>Archives of Gynecology and Obstetrics</i> , <b>2017</b> , 295, 1427-1433	2.5	3
98	Liver rupture in a 28-year-old primigravida with superimposed pre-eclampsia and hemolysis, elevated liver enzyme levels, and low platelet count syndrome. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2019</b> , 45, 1066-1070	1.9	3



97	Expression of H3K4me3 and H3K9ac in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2017-2027	4.9	3
96	Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 1923-1932	4.9	3
95	Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 1847-1855	4.9	3
94	Dopamine synthesis and dopamine receptor expression are disturbed in recurrent miscarriages. <i>Endocrine Connections</i> , <b>2018</b> , 7, 727-738	3.5	3
93	Extracapsular Lymph Node Involvement in Ovarian Carcinoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	3
92	Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. <i>Molecular and Clinical Oncology</i> , <b>2015</b> , 3, 1067-1072	1.6	3
91	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5031-5031	2.2	3
90	Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5504-5504	2.2	3
89	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
88	Local Resection of Primary Tumor in Upfront Stage IV Breast Cancer. <i>Breast Care</i> , <b>2016</b> , 11, 411-417	2.4	3
87	The role of EP3-receptor expression in cervical dysplasia. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 313-319	4.9	3
86	Delayed interval delivery in multiple gestations: the Munich experience. <i>Archives of Gynecology and Obstetrics</i> , <b>2019</b> , 299, 339-344	2.5	3
85	EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients. <i>Breast Care</i> , <b>2020</b> , 15, 171-177	2.4	3
84	Oropharyngeal HPV Detection Techniques in HPV-associated Head and Neck Cancer Patients. <i>Anticancer Research</i> , <b>2020</b> , 40, 2117-2123	2.3	3
83	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. <i>Archives of Gynecology and Obstetrics</i> , <b>2021</b> , 303, 1331-1345	2.5	3
82	Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. <i>Translational Oncology</i> , <b>2021</b> , 14, 100910	4.9	3
81	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 842	5.6	3
80	Cytoplasmic VDR expression as an independent risk factor for ovarian cancer. <i>Histochemistry and Cell Biology</i> , <b>2020</b> , 154, 421-429	2.4	2

79	Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. <i>Histochemistry and Cell Biology</i> , <b>2020</b> , 154, 189-195	2.4	2
78	Sex-specific epigenetic gene activation profiles are differentially modulated in human placentas affected by intrauterine growth restriction. <i>Journal of Reproductive Immunology</i> , <b>2020</b> , 139, 103124	4.2	2
77	Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. <i>Archives of Gynecology and Obstetrics</i> , <b>2020</b> , 301, 1267-1274	2.5	2
76	Towards individualised treatment in ovarian cancer. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 101-2	21.7	2
75	Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5005-5005	2.2	2
74	Expression of trophoblast derived prostaglandin E2 receptor 2 (EP2) is reduced in patients with recurrent miscarriage and EP2 regulates cell proliferation and expression of inflammatory cytokines. <i>Journal of Reproductive Immunology</i> , <b>2020</b> , 142, 103210	4.2	2
73	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
72	Integrin $\alpha 2 \beta 1$ Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	2
71	A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
70	Expression of the Carbohydrate Lewis Antigen, Sialyl Lewis A, Sialyl Lewis X, Lewis X, and Lewis Y in the Placental Villi of Patients With Unexplained Miscarriages. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 679424	8.4	2
69	Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status. <i>Archives of Gynecology and Obstetrics</i> , <b>2021</b> , 303, 217-230	2.5	2
68	First Evidence for a Role of Siglec-8 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
67	Pregnancy Zone Protein (PZP) is significantly upregulated in the decidua of recurrent and spontaneous miscarriage and negatively correlated to Glycodelin A (GdA). <i>Journal of Reproductive Immunology</i> , <b>2021</b> , 143, 103267	4.2	2
66	Comparison of Histone H3K4me3 between IVF and ICSI Technologies and between Boy and Girl Offspring. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
65	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. <i>Journal of Gynecologic Oncology</i> , <b>2021</b> , 32, e37	4	2
64	tRNA-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression.. <i>Cancers</i> , <b>2021</b> , 14,	6.6	2
63	LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
62	Spliceosome protein EFTUD2 is upregulated in the trophoblast of spontaneous miscarriage and hydatidiform mole. <i>Journal of Reproductive Immunology</i> , <b>2020</b> , 140, 103149	4.2	1

61	EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
60	The Distinct Roles of Transcriptional Factor KLF11 in Normal Cell Growth Regulation and Cancer as a Mediator of TGF- $\beta$ Signaling Pathway. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
59	RE: Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	1
58	No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas. <i>Journal of Neurology</i> , <b>2018</b> , 265, 431-432	5.5	1
57	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. <i>Breast Care</i> , <b>2018</b> , 13, 126-130	2.4	1
56	Effects of matcha tea extract on cell viability and peroxisome proliferator-activated receptor $\alpha$ expression on T47D breast cancer cells.. <i>Archives of Gynecology and Obstetrics</i> , <b>2022</b> , 1	2.5	1
55	AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1862	4.9	1
54	Factors Influencing the In Vitro Maturation (IVM) of Human Oocyte.. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
53	Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5565-5565	2.2	1
52	Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e17038-e17038	2.2	1
51	Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1	4.9	1
50	Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , <b>2021</b> ,	4.9	1
49	Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2020</b> , 80, 1221-1228	2	1
48	The risk of contralateral non sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16600-e16600	2.2	1
47	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5071-5071	2.2	1
46	Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2559-2574	4.9	1
45	L-Dopa-Decarboxylase (DDC) Is a Positive Prognosticator for Breast Cancer Patients and Epinephrine Regulates Breast Cancer Cell (MCF7 and T47D) Growth In Vitro According to Their Different Expression of. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
44	Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 6696-6704	3.1	1

43	Combined COX-2/PPAR $\gamma$ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	1
42	The decidual expression of Interleukin-7 is upregulated in early pregnancy loss. <i>American Journal of Reproductive Immunology</i> , <b>2021</b> , 86, e13437	3.8	1
41	Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
40	Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
39	A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.. <i>International Journal of Gynecological Cancer</i> , <b>2022</b> ,	3.5	1
38	Seasonal dynamic of cholecalciferol (D3) and anti-Muellerian hormone (AMH) with impact on ovarian response and IVF/ICSI.. <i>Archives of Gynecology and Obstetrics</i> , <b>2022</b> , 1	2.5	1
37	Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics. <i>Psycho-Oncology</i> , <b>2021</b> ,	3.9	1
36	Overexpression of galectin-4 in placentas of women with gestational diabetes.. <i>Journal of Reproductive Immunology</i> , <b>2022</b> , 151, 103629	4.2	1
35	Epigenetic changes occur in placentas of spontaneous and recurrent miscarriages.. <i>Journal of Reproductive Immunology</i> , <b>2021</b> , 149, 103466	4.2	0
34	The role of Interleukin-18 in recurrent early pregnancy loss. <i>Journal of Reproductive Immunology</i> , <b>2021</b> , 148, 103432	4.2	0
33	Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). <i>Breast Cancer Research</i> , <b>2021</b> , 23, 45	8.3	0
32	Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 442-448	4.9	0
31	Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gynecologic center in Germany. <i>Archives of Gynecology and Obstetrics</i> , <b>2021</b> , 1	2.5	0
30	Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report.. <i>Journal of Medical Case Reports</i> , <b>2022</b> , 16, 119	1.2	0
29	Galectin-8 and -9 as prognostic factors for cervical cancer.. <i>Archives of Gynecology and Obstetrics</i> , <b>2022</b> , 1	2.5	0
28	Gal-2 Increases H3K4me3 and H3K9ac in Trophoblasts and Preeclampsia. <i>Biomolecules</i> , <b>2022</b> , 12, 707	5.9	0
27	Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, e1103-e1110	3	
26	Evaluation of treatment patterns and prognosis in correlation with age in patients with vulvar cancer: A subset analysis of the AGO-CaRE-1 study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6090-6090	2.2	

25	Surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT): A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5562-5562	2.2
24	Resection margin and locoregional control in vulvar cancer: A subset analysis of the AGO CARE-1 multicenter study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5608-5608	2.2
23	Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5552-5552	2.2
22	Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5576-5576	2.2
21	Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5552-5552	2.2
20	Analysis of heat shock protein HSP27 secretion in an ovarian cancer cell model and detection of cell-free HSP27 in patient blood serum sample.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16570-e16570	2.2
19	Prognosis after local recurrence in vulvar cancer: A subset analysis of the AGO-CaRE-1 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5595-5595	2.2
18	The course of vulvar cancer: The utility of multistate models in the AGO-CaRE-1 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5596-5596	2.2
17	LKB1 and its importance for survival in EpCAM negative circulating tumor cells (CTC) in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e23061-e23061	2.2
16	How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5087-5087	2.2
15	Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5034-5034	2.2
14	Treatment reality in elderly patients with advanced ovarian cancer: A prospective analysis of the OVCAD consortium.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5058-5058	2.2
13	Recurrent ovarian cancer and management of elderly patients: Results of a prospective trial of treosulfan focusing on patient's preference and clinical outcome (NOGGO-Preference-Study).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e15520-e15520	2.2
12	Outcome parameters in node-negative vulvar cancer: A subset analysis of the AGO Care 1 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5531-5531	2.2
11	Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5593-5593	2.2
10	Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16535-e16535	2.2
9	Does alopecia predict response to chemotherapy and prognosis in patients with advanced ovarian cancer? A meta-analysis of prospective randomized phase III trials with 5,114 patients of the AGO meta data base.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5553-5553	2.2
8	Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5575-5575	2.2

7	Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral Metastatic Breast Cancer?. <i>Breast Care</i> , <b>2020</b> , 15, 527-533	2.4
6	MR Pelvimetry for Breech Presentation at Term- Interobserver Reliability, Incidental Findings and Reference Values. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , <b>2019</b> , 191, 424-432	2.3
5	Late Presentation at Primary Diagnosis of Breast Cancer: PatientsSPersonality Characteristics and Attitudes. <i>Breast Care</i> , <b>2021</b> , 16, 343-349	2.4
4	Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. <i>Journal of Ovarian Research</i> , <b>2021</b> , 14, 89	5.5
3	Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 713026	5.3
2	The role of resveratrol, Sirtuin1 and RXR $\alpha$ as prognostic markers in ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , <b>2021</b> , 1	2.5
1	Effects of intralipid infusions on anti-trophoblast antibody (ATAb)-activities in patients with recurrent pregnancy loss: An observational report.. <i>American Journal of Reproductive Immunology</i> , <b>2021</b> , e13506	3.8